- Home
- OPRX
as 12-20-2024 4:00pm EST
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 111.2M | IPO Year: | N/A |
| Target Price: | $8.25 | AVG Volume (30 days): | 335.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.78 - $16.65 | Next Earning Date: | 11-13-2024 |
| Revenue: | $88,179,506 | Revenue Growth: | 40.40% |
| Revenue Growth (this year): | 27.42% | Revenue Growth (next year): | 11.97% |
Stock Insider Trading Activity of OptimizeRx Corporation (OPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FEBBO WILLIAM J | OPRX | CEO | Dec 12 '24 | Buy | $5.01 | 20,000 | $100,220.00 | 601,253 |
Latest OptimizeRx Corporation News
OPRX Breaking Stock News: Dive into OPRX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Stephens Initiates Coverage on OptimizeRx With Equal Weight Rating, $5.50 Price Target
Simply Wall St.
a month ago
US Penny Stocks To Watch In November 2024
GlobeNewswire
a month ago
OptimizeRx to Participate in Upcoming Investor Conferences
MT Newswires
a month ago
B. Riley Lowers Price Target on OptimizeRx to $17 From $18.50, Keeps Buy Rating
MT Newswires
a month ago
RBC Cuts Price Target on OptimizeRx to $7 From $14, Keeps Outperform Rating
GuruFocus.com
a month ago
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ...
Zacks
a month ago
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates
GlobeNewswire
a month ago
OptimizeRx Reports Third Quarter 2024 Financial Results
Compare OPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPRX OptimizeRx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.